A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer
A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer
Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.
Inclusion Criteria:
Exclusion Criteria: